Apr. 2025 Fineline Deals Book
China Pharmaceutical BD Transaction Review – Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. – Fineline Deals Book Apr. 2025
According to incomplete statistics from Fineline Info & Tech, there were a total of 15 pharmaceutical BD and M&A transactions in China in Apr 2025, including 13 outbound China and 2 domestic Transactions.
Outbound China
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary, Shanghai Henlius Biotech (HKG: 2696), has completed a clinical trial filing for HLX301 in Australia. Henlius will conduct a Phase I clinical study in the country for the bispecific antibody (BsAb) targeting programmed-death-ligand 1 (PD-L1) and T cell immunoglobulin and ITIM domains (TIGIT) in locally advanced or metastatic solid tumors…. [Full Artical]
Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South Korea-headquartered Alvogen Korea Co., Ltd. regarding its HanSiZhuang (serplulimab) drug…. [Full Artical]
Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development
China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics…. [Full Artical]
QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with US-headquartered Caldera Therapeutics for its preclinical long-acting bispecific antibody (BsAb) QX030N, targeting autoimmune diseases. This strategic partnership underscores QYuns’ commitment to advancing innovative therapies in the autoimmune space… [Full Artical]
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and WuXi AppTec in 2016, announced a technology licensing agreement with Juno. Upon approval from independent shareholders, JW Therapeutics will grant Juno a nonexclusive license to its JW sLVV production process and related technical knowledge. In return, Juno will pay JW Therapeutics up to USD 10 million…. [Full Artical]
Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102
Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo’s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China…. [Full Artical]
Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi’s commitment to expanding its portfolio in these therapeutic areas…. [Full Artical]
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply agreements with Thailand’s Interpharma Public Company Limited. The agreements cover NVK002, a topical ophthalmic atropine solution for pediatric myopia progression; Brimochol PF, a presbyopia treatment; and six generic glaucoma medications, including bimatoprost, bimatoprost timolol, latanoprost, latanoprost timolol, travoprost, and travoprost timolol…. [Full Artical]
Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment
Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled Phase II study to evaluate the efficacy and safety of its Brimochol PF in Chinese patients with presbyopia. The study, which has completed its first patient enrollment, is expected to enroll 119 patients across 14 centers, marking a significant step in the development of this novel therapy…. [Full Artical]
HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc., through Synthego Corporation, marking a significant expansion into new therapeutic territories. The agreement allows Vita to utilize HuidaGene’s high-fidelity CRISPR-Cas12 technology in developing cell therapies for neuromuscular disorders…. [Full Artical]
Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with German pharmaceutical giant Merck KGaA (ETR: MRK) for its oral non-peptide GnRH receptor antagonist, SHR7280. This collaboration focuses on advancing SHR7280 in the field of assisted reproduction, with Merck securing exclusive commercialization rights in mainland China…. [Full Artical]
Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its German partner Merck KGaA (ETR: MRK) has exercised the global commercialization option for pimicotinib (ABSK021). This move triggers an option exercise fee of USD 85.0 million, as per the agreement signed in December 2023…. [Full Artical]
Organon Acquires U.S. Rights to TOFIDENCE from Biogen
Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (NASDAQ: BIIB). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021…. [Full Artical]
Dometsic Transactions in China
Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million (USD 2.7 million) in Lingyi Biotech Co., Ltd., a domestic gene therapy specialist. Additionally, Jolly Pharma has secured priority rights to obtain the distribution rights or sales agency rights for Lingyi Bio’s LY-N001, a drug for Parkinson’s disease (PD), in mainland China…. [Full Artical]
Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a commercialization partnership with Beijing Jiluntai Pharmaceutical Co., Ltd (Radio technology). Under the agreement, Baheal secures the rights to commercialize Jiluntai’s Category 1 nuclear pharmaceutical drug, Technetium-99m-labeled hydrazinylnicotinamide-polyethylene glycol-bicyclic RGD peptide, in mainland China….[Full Artical]
For more insights, follow Fineline Info & Tech